Stryker Co. (NYSE:SYK) VP Yin C. Becker sold 23,221 shares of the business’s stock in a transaction dated Friday, March 9th. The stock was sold at an average price of $165.96, for a total value of $3,853,757.16. Following the sale, the vice president now owns 10,499 shares in the company, valued at $1,742,414.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Shares of Stryker Co. (NYSE SYK) traded up $1.48 on Monday, reaching $167.89. The company’s stock had a trading volume of 1,536,290 shares, compared to its average volume of 1,383,297. Stryker Co. has a 12-month low of $129.59 and a 12-month high of $170.00. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.59 and a current ratio of 2.29. The firm has a market capitalization of $63,040.00, a price-to-earnings ratio of 34.34, a PEG ratio of 2.39 and a beta of 0.70.
Stryker (NYSE:SYK) last issued its quarterly earnings results on Tuesday, January 30th. The medical technology company reported $1.96 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.95 by $0.01. Stryker had a return on equity of 24.56% and a net margin of 8.20%. The firm had revenue of $3.47 billion for the quarter, compared to analyst estimates of $3.42 billion. During the same period in the previous year, the firm earned $1.78 earnings per share. The company’s revenue was up 9.9% compared to the same quarter last year. equities research analysts expect that Stryker Co. will post 7.12 EPS for the current fiscal year.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Chemical Bank lifted its stake in Stryker by 24.1% in the fourth quarter. Chemical Bank now owns 12,936 shares of the medical technology company’s stock valued at $2,003,000 after buying an additional 2,515 shares during the period. Green Square Capital LLC lifted its stake in Stryker by 148.5% in the fourth quarter. Green Square Capital LLC now owns 5,606 shares of the medical technology company’s stock valued at $871,000 after buying an additional 3,350 shares during the period. Rehmann Capital Advisory Group lifted its stake in Stryker by 7.8% in the fourth quarter. Rehmann Capital Advisory Group now owns 5,306 shares of the medical technology company’s stock valued at $822,000 after buying an additional 385 shares during the period. Colonial Trust Advisors lifted its stake in Stryker by 40.9% in the fourth quarter. Colonial Trust Advisors now owns 33,883 shares of the medical technology company’s stock valued at $5,246,000 after buying an additional 9,836 shares during the period. Finally, Xact Kapitalforvaltning AB lifted its stake in Stryker by 7.3% in the fourth quarter. Xact Kapitalforvaltning AB now owns 57,539 shares of the medical technology company’s stock valued at $8,909,000 after buying an additional 3,912 shares during the period. 75.71% of the stock is currently owned by hedge funds and other institutional investors.
SYK has been the topic of several research reports. Robert W. Baird upgraded Stryker from a “neutral” rating to an “outperform” rating and boosted their price target for the stock from $161.00 to $173.00 in a report on Thursday, November 16th. JPMorgan Chase & Co. upgraded Stryker from a “neutral” rating to an “overweight” rating in a report on Tuesday, January 2nd. ValuEngine upgraded Stryker from a “hold” rating to a “buy” rating in a report on Tuesday, November 14th. Needham & Company LLC restated a “hold” rating on shares of Stryker in a report on Thursday, December 7th. Finally, Royal Bank of Canada restated a “buy” rating and set a $175.00 price target on shares of Stryker in a report on Tuesday, January 9th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and fifteen have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $163.85.
COPYRIGHT VIOLATION WARNING: “Yin C. Becker Sells 23,221 Shares of Stryker Co. (SYK) Stock” was reported by American Banking News and is the property of of American Banking News. If you are accessing this article on another publication, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/03/12/yin-c-becker-sells-23221-shares-of-stryker-co-syk-stock.html.
Stryker Company Profile
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.